/Investor DB

Lifeforce Capital — 2022 Investments

6 investments dated 2022 · listed companies and verified rows first · show all

Aspen Neuroscienceaspenneuroscience.comin𝕏May 2022✓ verified

Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.

BiotechDeep TechDigital HealthMedical DevicesSan Diego, US

Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)

Co-investorsARCH Venture PartnersOrbiMedDomain AssociatesEDB InvestmentsSection 32Frazier Life Sciences+10 more

64x64-x.comin𝕏Jan 2022 · $55M

64x provides a platform and product suite for manufacturing advanced therapeutics, including gene therapies, cell therapies, and biologics.

BiotechDeep TechMedical Devices

Co-investorsBoxGroupFirst Round CapitalFifty YearsFuture VenturesNorthpond VenturesRefactor Capital+1 more

64x Bio64xbio.comin𝕏Series A · Jan 2022 · $55M

64x Bio develops cell-line engineering and production technologies to overcome manufacturing bottlenecks in advanced and next-generation therapies.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSan Francisco, US

Lexi Rovner(CEO, Co-founder, Board of Directors)inAlexis Rovner(Founder)Ryan GallagherEmily Hawkins(Head of Talent)George Church, PhD(Co-founder, Scientific Advisory Board)David Thompson, PhD(Co-founder, Scientific Advisory Board)

Co-investorsFifty YearsFuture VenturesG VenturesRaptor GroupY CombinatorAlix Ventures+8 more

MindRightmindright.ioinSeed · May 2022 · $2M

MindRight Health provides culturally affirming mental health support through a community-based platform and network of peer supporters.

Digital HealthHealthtechMental HealthSaaSWellness & FitnessMiami, US

Ashley Edwards(Founder)inAlexander Phillip Zito(Executive Officer)Jacob Slome Rauchbach(Executive Officer, Director)

Co-investorsAcumen AmericaDigitalDx VenturesGaingelsImpact America Fund

Ochreochre.bioOct 2022 · $30M

Liver transplant and drug testing

Co-investorsSelvedge Ventureah! VenturesKhosla VenturesNorrsken VC

Ochre Bioochre-bio.comin𝕏Series A · Oct 2022

Ochre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models.

AI & Machine LearningBiotechHealthtechMedical DevicesLondon, GB

Quin Wills(Founder/CSO)inJack O'Meara(Founder)in

BoardChinwe UkomaduElaine SullivanEliot ForsterJack Castle

Co-investorsBackedBeast VenturesCoastCapEntrepreneur FirstExpaGaingels+18 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.